Tag: PAA
PharmAust receives grant from FightMND for monepantel phase one trial in motor neuron disease
Motor neurone disease (MND) charity FightMND has awarded oncology company PharmAust (ASX: PAA) a grant for a Phase 1 trial to examine the effects of its flagship drug candidate monepantel on the disea...
PharmAust lays out market strategy for lead drug monepantel
Oncology company PharmAust (ASX: PAA) has provided a timely update to the market concerning developments of its lead drug candidate, monepantel (MPL).
PharmAust is currently progressing the drug in...
PharmAust confirms monepantel’s anti-viral potential in fight against COVID-19
Determined to become one of the first companies to develop an active treatment for COVID-19, oncology company PharmAust (ASX: PAA) has reported it has successfully repeated a second round of in-vitro ...
PharmAust subsidiary Epichem signs JV to develop waste-to-fuels technology
PharmAust (ASX: PAA) subsidiary Epichem has entered into a 50:50 joint venture agreement with Western Australia-based private company Obsidian Minerals to develop a novel and disruptive waste-to-fuels...
PharmAust trims losses as monepantel drug development progresses
Oncology company PharmAust (ASX: PAA) has narrowed its losses for the full year as it celebrated many achievements in the overall development of its lead cancer drug, monepantel (MPL).
MPL is a vet...
PharmAust research shows monepantel can inhibit progression of SARS-CoV-2 virus
Preliminary research findings on PharmAust’s (ASX: PAA) lead candidates monepantel and monepantel sulfone have demonstrated that application of the drugs on human respiratory cells can inhibit the pro...
PharmAust clinical trials show monepantel fights COVID-19 infectivity, improves prognosis for canines with cancer
Clinical stage oncology company PharmAust (ASX: PAA) has attributed a successful June quarter performance to lead drug monepantel and monepantel sulfone which has shown “remarkable” early results agai...
Repeat experiment proves PharmAust’s lead cancer drug can reduce infectivity of COVID-19 cells
A repeat preliminary evaluation of PharmAust’s (ASX: PAA) lead cancer drug monepantel and monepantel sulfone has found it can reduce transmission in cells infected with the current SARS-CoV-2 strain o...
Studies show PharmAust’s lead cancer drug could suppress COVID-19 infectivity
Preliminary clinical work by PharmAust (ASX: PAA) on the effects of its lead candidate monepantel and monepantel sulfone on cells infected with COVID-19 has demonstrated potential suppression of the v...
PharmAust makes progress towards next clinical trial of monepantel
Oncology company PharmAust (ASX: PAA) came out of a trading halt this morning with news that its monepantel canine trial achieved a “successful outcome” with phase 3 trials already on the horizon.
...
PharmAust and U-Vet gear up for Phase 2 clinical trial of leading drug candidate monepantel
Oncology company PharmAust (ASX: PAA) is on the home straight to commencing a milestone drug trial following the finalisation of contractual arrangements for its Phase 2 canine cancer trial, to be com...
PharmAust reports positive results from phase I anti-cancer tablet trial on dogs
Clinical-stage oncology company PharmAust (ASX: PAA) has received early positive results from a phase I trial of its reformulated monepantel anti-cancer tablets.
The canine-based trial commenced la...
PharmAust to begin anti-cancer tablet trials in dogs this month
Oncology company PharmAust (ASX: PAA) has manufactured its first batch of monepantel anti-cancer tablets in readiness for the phase I clinical trial in dogs, which will begin later this month.
The ...
PharmAust’s principal metabolite confirmed to have anti-cancer properties
Oncology company PharmAust (ASX: PAA) has revealed positive news in relation to its ongoing development of monepantel, with the company confirming that monepantel’s major metabolite has exhibited anti...
PharmAust readies to upscale its flagship cancer drug candidate Monepantel
Clinical-stage oncology company PharmAust (ASX: PAA) could be set to upscale development of its flagship drug candidate ‘Monepantel’, a cancer drug that is potentially both applicable to humans as wel...
PharmAust targets unique market for treating cancer in dogs
Australian vets and dog-lovers could soon have an additional weapon in their toolkit to treat cancer in dogs, courtesy of a novel therapy to be developed by oncology company PharmAust’s (ASX: PAA) who...
PharmAust secures US patent for cancer drugs
PharmAust (ASX: PAA) has locked in a US patent for its aminoacetonitrile compound drug portfolio, which have anti-cancer properties.
“Allowance of this patent secures PharmAust’s ownership for over...
